CAMBRIDGE, Mass. , Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the

Immunosynthen ADCs activate the STING pathway in both tumor-resident immune cells and in the tumor   cells , resulting in robust anti-tumor activity and offer ing a differentiated approach from other innate immune activators  CAMBRIDGE, Mass. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mersana

- Webcast to be held on Monday, November 16, 2020, at 8:00 a.m. ET - CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs)

Presented additional data from XMT-1536 Phase 1 study at ESMO demonstrating compelling and consistent activity and tolerability profile in ovarian cancer Received FDA Fast Track Designation for XMT-1536 for p atients with h eavily- p retreated   o varian c ancer Ended Q3 2020 with $ 27 1 million in

CAMBRIDGE, Mass. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

CAMBRIDGE, Mass. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

CAMBRIDGE, Mass. , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that

- Maintained 34% objective response rate and 79% disease control rate, including two complete responses   - XMT-1536 continues to be generally well-tolerated with no new safety signals - Data to be presented and discussed during a conference call today at 8 a.m. ET CAMBRIDGE, Mass. , Sept.

-  Company to Host Conference Call and Webcast Featuring Study Investigator, Erika Hamilton, MD on September 17, 2020 at 8:00 a.m. ET - CAMBRIDGE, Mass. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering

CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that